Metabolomic Study of Obesity and Its Treatment with Palmitoylated Prolactin-Releasing Peptide Analog in Spontaneously Hypertensive and Normotensive Rats

Show simple item record
dc.contributor.authorČermáková, Martina
dc.contributor.authorPelantová, Helena
dc.contributor.authorNeprašová, Barbora
dc.contributor.authorŠedivá, Blanka
dc.contributor.authorMaletínská, Lenka
dc.contributor.authorKuneš, Jaroslav
dc.contributor.authorTomášová, Petra
dc.contributor.authorŽelezná, Blanka
dc.contributor.authorKuzma, Marek
dc.date.accessioned2019-07-08T10:00:13Z
dc.date.available2019-07-08T10:00:13Z
dc.date.issued2019
dc.description.abstract-translatedIn this study, the combination of metabolomics and standard biochemical and biometric parameters was used to describe the metabolic effects of diet-induced obesity and its treatment with the novel antiobesity compound palm11-PrRP31 (palmitoylated prolactin-releasing peptide) in spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY). The results showed that SHR on a high-fat (HF) diet were normoglycemic with obesity and hypertension, while WKY on the HF diet were normotensive and obese with prediabetes. NMR-based metabolomics revealed mainly several microbial cometabolites altered by the HF diet, particularly in urine. The HF diet induced similar changes in both models. However, two groups of genotype-specific metabolites were defined: metabolites specific to the genotype at baseline (e.g., 1-methylnicotinamide, phenylacetylglycine, taurine, methylamine) and metabolites reacting specifically to the HF diet in individual genotypes (2-oxoglutarate, dimethylamine, N-butyrylglycine, p-cresyl sulfate). The palm11-PrRP31 lowered body weight and improved biochemical and biometric parameters in both strains, and it improved glucose tolerance in WKY rats on the HF diet. In urine, the therapy induced significant decrease of formate and 1-methylnicotinamide in SHR and alanine, allantoin, dimethylamine, and N-butyrylglycine in WKY. Altogether, our study confirms the effectiveness of palm11-PrRP31 for antiobesity treatment.en
dc.format16 s.cs
dc.format.mimetypeapplication/pdf
dc.identifier.citationČERMÁKOVÁ, M., PELANTOVÁ, H., NEPRAŠOVÁ, B., ŠEDIVÁ, B., MALETÍNSKÁ, L., KUNEŠ, J., TOMÁŠOVÁ, P., ŽELEZNÁ, B., KUZMA, M. Metabolomic Study of Obesity and Its Treatment with Palmitoylated Prolactin-Releasing Peptide Analog in Spontaneously Hypertensive and Normotensive Rats. Journal of proteome research, 2019, roč. 18, č. 4, s. 1735-1750. ISSN 1535-3893.en
dc.identifier.document-number464068900024
dc.identifier.doi10.1021/acs.jproteome.8b00964
dc.identifier.issn1535-3893
dc.identifier.obd43926020
dc.identifier.uri2-s2.0-85063953402
dc.identifier.urihttp://hdl.handle.net/11025/34864
dc.language.isoenen
dc.publisherAmerican Chemical Societyen
dc.rightsPlný text není přístupný.cs
dc.rights© American Chemical Societyen
dc.rights.accessclosedAccessen
dc.subject.translatedantiobesity therapyen
dc.subject.translatedhigh-fat dieten
dc.subject.translatedhypertensionen
dc.subject.translatedmetabolomicsen
dc.subject.translatedNMRen
dc.subject.translatedobesityen
dc.titleMetabolomic Study of Obesity and Its Treatment with Palmitoylated Prolactin-Releasing Peptide Analog in Spontaneously Hypertensive and Normotensive Ratsen
dc.typečlánekcs
dc.typearticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen

Files

Collections

OBD
 Articles (KMA)